Opportunity assessment
Review unmet need, scientific rationale, existing evidence, patient impact, and feasibility.
Research & development
Development built around evidence, usability, and unmet need.
Our programmes evaluate how established and emerging therapies can be delivered more effectively, supported by relevant clinical evidence and responsible collaboration.
Current focus
Neurology, alternative administration, treatment experience, and evidence generation.
Our development lens
Better therapies require more than a new active ingredient.
We assess formulation, delivery, tolerability, treatment burden, monitoring, and patient-reported outcomes alongside traditional clinical measures.
- Reformulation and alternative delivery concepts
- Clinical evidence and protocol collaboration
- Device and administration usability
- Quality-of-life and patient-experience measures
Development pathway
A disciplined progression from idea to lifecycle evidence.
Technical development
Explore formulation, route of administration, device considerations, stability, and manufacturing pathways.
Clinical evidence
Define questions that matter to patients, clinicians, and healthcare decision-makers.
Launch preparation
Coordinate medical information, quality documentation, supply readiness, and local-market requirements.
Lifecycle learning
Review safety, use patterns, new evidence, product quality, and opportunities for improvement.
Featured research
Advanced Parkinson's disease and apomorphine delivery.
Bastian's legacy research interests include approaches to help appropriate patients receive apomorphine therapy through less intrusive and more usable delivery options.
Patient selection
Evidence that helps care teams identify people most likely to benefit from treatment.
Administration
Continuous and intermittent delivery concepts designed around ease of use and tolerability.
Meaningful outcomes
Measurement approaches that reflect mobility, daily life, treatment burden, and quality of life.
Clinical trial reference
TOLEDO study
The TOLEDO programme evaluated apomorphine subcutaneous infusion in patients with advanced Parkinson's disease. External trial records and the archived study protocol remain available for scientific reference.
Data-sharing principles
Appropriately qualified researchers may submit scientifically valid proposals for access to eligible de-identified study information, subject to independent review, participant privacy, legal requirements, and applicable study-specific conditions.
Availability and scope vary by study. Contact the medical team for current eligibility, documentation, and review requirements.
Research collaboration
Have a development programme that fits our focus?
We welcome well-defined opportunities across formulation, clinical research, medical devices, evidence generation, and regional development.